Interactions between the cytochrome P450 system and the second-generation antipsychotics

被引:0
作者
Prior, TI
Baker, GB
机构
[1] Alberta Hosp, Edmonton, AB T5J 2J7, Canada
[2] Univ Alberta, Dept Psychiat, Bebensee Schizophrenia Res Unit, Edmonton, AB, Canada
[3] Univ Alberta, Dept Psychiat, Neurochem Res Unit, Edmonton, AB, Canada
来源
JOURNAL OF PSYCHIATRY & NEUROSCIENCE | 2003年 / 28卷 / 02期
关键词
antipsychotic agents; biotransformation; cytochrome P-450 enzyme system; drug interactions; metabolism; schizophrenia;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Awareness of the metabolism of second-generation antipsychotics by the cytochrome P450 (CYP) system can inform the clinician about how to avoid and manage drug-drug interactions involving these enzymes. Clozapine is metabolized primarily by CYP1A2, with additional contributions by CYP2CI9, CYP2D6 and CYP3A4. Risperidone is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4. Olanzapine is metabolized primarily by CYP1A2 and to a lesser extent by CYP2D6. Quetiapine and ziprasidone are metabolized by CYP3A4. At the usual clinical doses, these drugs appear not to significantly affect the metabolism of other medications. There is, however, a lack of in vivo metabolic data, especially for the 3 newest second-generation antipsychotics: olanzapine, quetiapine and ziprasidone.
引用
收藏
页码:99 / 112
页数:14
相关论文
共 126 条
[51]   Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine [J].
Jeppesen, U ;
Gram, LF ;
Vistisen, K ;
Loft, S ;
Poulsen, HE ;
Brosen, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (01) :73-78
[52]   Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide [J].
Jeppesen, U ;
Rasmussen, BB ;
Brosen, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) :279-286
[53]   FLUVOXAMINE INHIBITION AND CARBAMAZEPINE INDUCTION OF THE METABOLISM OF CLOZAPINE - EVIDENCE FROM A THERAPEUTIC DRUG-MONITORING SERVICE [J].
JERLING, M ;
LINDSTROM, L ;
BONDESSON, U ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1994, 16 (04) :368-374
[54]   Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method [J].
Jerling, M ;
Merle, Y ;
Mentre, F ;
Mallet, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (05) :447-453
[55]   Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection [J].
Joos, AAB ;
Frank, UG ;
Kaschka, WP .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (01) :83-85
[56]   Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer [J].
Joos, AAB ;
Konig, F ;
Frank, UG ;
Kaschka, WP ;
Morike, KE ;
Ewald, R .
PHARMACOPSYCHIATRY, 1997, 30 (06) :266-270
[57]   Drug metabolism in hepatocyte sandwich cultures of rats and humans [J].
Kern, A ;
Bader, A ;
Pichlmayr, R ;
Sewing, KF .
BIOCHEMICAL PHARMACOLOGY, 1997, 54 (07) :761-772
[58]  
KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8
[59]   Increase in plasma levels of clozapine and norclozapine after administration of nefazodone [J].
Khan, AY ;
Preskorn, SH .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (05) :375-376
[60]   Fluvoxamine increases the clozapine serum levels significantly [J].
Koponen, HJ ;
Leinonen, E ;
Lepola, U .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1996, 6 (01) :69-71